Aileron Therapeutics, Inc. (ALRN), a Boston-based biopharmaceutical company, has announced its rebranding to Rein Therapeutics, Inc. This transformation includes a new name, logo, website, and overall branding, all reflecting the company's dedication to developing groundbreaking treatments for various diseases.
Starting January 13, 2025, the company's stock will be traded under the new Nasdaq ticker symbol "RNTX." The CUSIP number for its common stock will remain the same.
As of now, the stock is trading at $2.01, marking a 4.15% increase on the Nasdaq Capital Market.
